{"id":9283,"date":"2024-09-25T13:36:06","date_gmt":"2024-09-25T10:36:06","guid":{"rendered":"https:\/\/yalovasondakika.com.tr\/?p=9283"},"modified":"2024-09-25T13:36:06","modified_gmt":"2024-09-25T10:36:06","slug":"yerli-ilac-firmasi-genden-sedef-hastaliginin-tedavisine-yonelik-umut-veren-calisma-yenilikci-arastirma-ilaci-gn-037nin-faz-2-sonuclari-aciklandi","status":"publish","type":"post","link":"https:\/\/yalovasondakika.com.tr\/index.php\/2024\/09\/25\/yerli-ilac-firmasi-genden-sedef-hastaliginin-tedavisine-yonelik-umut-veren-calisma-yenilikci-arastirma-ilaci-gn-037nin-faz-2-sonuclari-aciklandi\/","title":{"rendered":"Yerli ila\u00e7 firmas\u0131 GEN’den sedef hastal\u0131\u011f\u0131n\u0131n tedavisine y\u00f6nelik umut veren \u00e7al\u0131\u015fma: Yenilik\u00e7i ara\u015ft\u0131rma ilac\u0131 GN-037’nin Faz 2 sonu\u00e7lar\u0131 a\u00e7\u0131kland\u0131!"},"content":{"rendered":"

GEN, form\u00fclasyonunu b\u00fcnyesindeki AR-GE laboratuvarlar\u0131nda geli\u015ftirdi\u011fi yenilik\u00e7i ilac\u0131 olan GN-037 topikal kreminin Faz 2 klinik ara\u015ft\u0131rma sonu\u00e7lar\u0131n\u0131 payla\u015ft\u0131. Bahis ile ilgili a\u00e7\u0131klama yapan GEN Y\u00f6netim Kurulu Lideri ve Genel M\u00fcd\u00fcr\u2019\u00fc Abidin G\u00fclm\u00fc\u015f, \u201cGN-037\u2019nin Faz 2 klinik ara\u015ft\u0131rmas\u0131n\u0131n m\u00fcspet sonu\u00e7lar\u0131n\u0131 duyurmaktan \u00f6t\u00fcr\u00fc heyecanl\u0131y\u0131z. Yenilik\u00e7i ara\u015ft\u0131rma eserimizin, t\u00fcm d\u00fcnyadaki sedef hastalar\u0131 i\u00e7in kaliteli ve tesirli bir tahlil sunaca\u011f\u0131na inan\u0131yoruz\u201d bi\u00e7iminde konu\u015ftu.<\/strong><\/p>\n

T\u00fcrk ila\u00e7 b\u00f6l\u00fcm\u00fcn\u00fcn en s\u00fcratli b\u00fcy\u00fcyen firmalar\u0131ndan biri olan GEN, sedef hastal\u0131\u011f\u0131n\u0131n tedavisine y\u00f6nelik geli\u015ftirdi\u011fi GN-037 tropikal kremi ile ilgili y\u00fcr\u00fct\u00fclen \u00e7al\u0131\u015fmalar\u0131ndan umut veren sonu\u00e7lar payla\u015ft\u0131.<\/p>\n

Sedef hastal\u0131\u011f\u0131 \u00e7e\u015fitli klinik bi\u00e7imlerde ortaya \u00e7\u0131kabilen, yineleyici, kronik bir deri hastal\u0131\u011f\u0131d\u0131r. S\u0131kl\u0131\u011f\u0131 farkl\u0131 toplumlarda ve co\u011frafik b\u00f6lgelerde de\u011fi\u015fiklik g\u00f6steren hastal\u0131k, genel pop\u00fclasyonda %1,5-2 oran\u0131nda g\u00f6r\u00fclmektedir.\u00a0Sedef hastalar\u0131n\u0131n %70-80\u2019i s\u0131n\u0131rl\u0131\/lokalize hastal\u0131\u011fa sahip olup s\u0131rf topikal tedavi ile y\u00f6netilmektedir. Bu taraf\u0131yla topikal tedavi, sedef hastal\u0131\u011f\u0131 idaresindeki en yayg\u0131n tedavi formudur. Mevcut bilgilere nazaran \u00fclkemizde yakla\u015f\u0131k 1.300.000 sedef hastas\u0131n\u0131n bulundu\u011fu ve bu hastalar\u0131n yakla\u015f\u0131k 900.000\u2019inin topikal ila\u00e7larla tedavi edildi\u011fi iddia edilmektedir.<\/p>\n

Form\u00fclasyonu GEN\u2019in AR-GE laboratuvarlar\u0131nda geli\u015ftirilen ve klinik ara\u015ft\u0131rma geli\u015ftirme safhas\u0131ndaki GN-037 topikal krem, hafif ve orta \u015fiddetli plak tipi sedef hastal\u0131\u011f\u0131n\u0131n (psoriasisin) tedavisi i\u00e7in yenilik\u00e7i bir tahlil sunmay\u0131 hedefliyor. Faz 1 klinik ara\u015ft\u0131rmas\u0131n\u0131n sonu\u00e7lar\u0131, milletleraras\u0131 alanda en sayg\u0131n ve itibarl\u0131 bilimsel yay\u0131nlardan biri olan \u2018Dermatology and Therapy\u2019 mecmuas\u0131nda yay\u0131mlanan GN-037\u2019nin\u00a0Faz 2 klinik ara\u015ft\u0131rma sonu\u00e7lar\u0131, 25-28 Eyl\u00fcl 2024 tarihleri ortas\u0131nda Amsterdam\u2019da ger\u00e7ekle\u015ftirilmekte olan Avrupa Dermatoloji ve Veneroloji Akademisi (European Academy of Dermatology and Venereology) 2024 Kongresi\u2019nde a\u00e7\u0131kland\u0131. \u00a0<\/p>\n

Yap\u0131lan a\u00e7\u0131klamada, Faz 2 klinik ara\u015ft\u0131rmas\u0131na T\u00fcrkiye\u2019deki 19 ara\u015ft\u0131rma merkezinden dahil edilen toplamda 190 hafif ve orta \u015fiddetli plak tipi sedef hastal\u0131\u011f\u0131 bulunan g\u00f6n\u00fcll\u00fclerin datalar\u0131na nazaran, topikal olarak uygulanan GN-037 kreminin, plasebo uygulanan hastalara nazaran istatistiksel olarak manal\u0131 bi\u00e7imde tesirli ve \u00fcst\u00fcn tedavi ba\u015far\u0131s\u0131 sa\u011flad\u0131\u011f\u0131 a\u00e7\u0131kland\u0131.<\/p>\n

AB\u0130D\u0130N G\u00dcLM\u00dc\u015e: \u201cGN-037\u2019N\u0130N AKT\u0130FL\u0130\u011e\u0130NE Y\u00d6NEL\u0130K \u00c7ALI\u015eMALARIMIZ T\u00dcM S\u00dcRAT\u0130YLE DEVAM ED\u0130YOR\u201d<\/strong><\/p>\n

GEN Y\u00f6netim Kurulu Lideri ve Genel M\u00fcd\u00fcr\u2019\u00fc Abidin G\u00fclm\u00fc\u015f,\u00a0GEN\u2019in ara\u015ft\u0131rma ilac\u0131 GN-037 topikal kreminin Faz 2 klinik ara\u015ft\u0131rmas\u0131n\u0131n sonu\u00e7lar\u0131n\u0131n EADV 2024 Kongresi\u2019nde a\u00e7\u0131klanmas\u0131 ile ilgili \u015fu de\u011ferlendirmeleri yapt\u0131:<\/p>\n

\u201cYerli bir ila\u00e7 firmas\u0131 olarak daldaki 25 y\u0131ll\u0131k deneyimimizle, az hastal\u0131klar ve kar\u015f\u0131lanmam\u0131\u015f s\u0131hhat gereksinimlerine y\u00f6nelik g\u00fcvenilirli\u011fi k\u00fcresel \u00f6l\u00e7ekte kan\u0131tlanm\u0131\u015f, kaliteli ve inovatif tahliller sunmak i\u00e7in faaliyetlerimizi s\u00fcrd\u00fcr\u00fcyoruz. Bu misyonumuz do\u011frultusunda, \u00fclkemizde de yakla\u015f\u0131k 900 bin sedef hastas\u0131n\u0131n kulland\u0131\u011f\u0131 topikal tedavi usullerine yenilik\u00e7i bir tahlil getirmeyi hedefleyen GN-037 kremini geli\u015ftirerek \u00e7al\u0131\u015fmalar\u0131m\u0131za uzun vakit evvel ba\u015flad\u0131k. Yakla\u015f\u0131k 1 y\u0131l \u00fczere k\u0131sa bir m\u00fcddette hasta al\u0131m\u0131 tamamlanan, GN-037\u2019nin Faz 2 klinik ara\u015ft\u0131rmas\u0131n\u0131n m\u00fcspet sonu\u00e7lar\u0131n\u0131 duyurmaktan \u00f6t\u00fcr\u00fc heyecanl\u0131y\u0131z. Yenilik\u00e7i ara\u015ft\u0131rma eserimizin, t\u00fcm d\u00fcnyadaki sedef hastalar\u0131 i\u00e7in kaliteli ve tesirli bir tahlil sunaca\u011f\u0131na inan\u0131yoruz. T\u00fcrkiye\u2019nin \u00f6nde gelen ila\u00e7 \u015firketlerinden biri olarak, GN-037\u2019yi en k\u0131sa m\u00fcddette hastalar\u0131m\u0131z\u0131n kullan\u0131m\u0131na sunmak hedefiyle \u00e7al\u0131\u015fmalar\u0131m\u0131za t\u00fcm s\u00fcratiyle devam etti\u011fimizi kamuoyuyla payla\u015fmaktan memnunluk duyuyoruz.\u201d<\/p>\n

GEN Ar-Ge ve Klinik Operasyonlar Genel M\u00fcd\u00fcr Yard\u0131mc\u0131s\u0131 Uzm. Dr. Nadir Ulu ise \u015fu a\u00e7\u0131klamay\u0131 yapt\u0131:<\/p>\n

\u201cPlak tipi sedef hastal\u0131\u011f\u0131na sahip olan bireyler, tedavileri m\u00fchletince farkl\u0131 topikal casuslar\u0131n t\u0131pk\u0131 anda uygulanmas\u0131n\u0131 gerektiren g\u00fc\u00e7l\u00fc devirlerle kar\u015f\u0131la\u015fmaktad\u0131r. Hastalar\u0131n ya\u015fad\u0131\u011f\u0131 bu g\u00fc\u00e7l\u00fc durum, onlar\u0131n ahengini art\u0131racak yeni kombine ila\u00e7lara ihtiya\u00e7 oldu\u011funun alt\u0131n\u0131 \u00e7izmektedir. Yenilik\u00e7i topikal kremimiz ile ger\u00e7ekle\u015ftirdi\u011fimiz Faz 2 klinik ara\u015ft\u0131rmam\u0131zda, t\u00fcm primer ve sekonder sonlan\u0131m noktalar\u0131 bak\u0131m\u0131ndan GN-037 kreminin plaseboya nazaran daha \u00fcst\u00fcn sonu\u00e7lar sa\u011flad\u0131\u011f\u0131 ve birebir vakitte ek bir g\u00fcvenlilik sorunu olu\u015fturmad\u0131\u011f\u0131 i\u00e7in b\u00fcy\u00fck memnunluk duyuyoruz. Faz 2 ara\u015ft\u0131rmam\u0131z\u0131 y\u00fcr\u00fcten t\u00fcm ara\u015ft\u0131rmac\u0131lara, ara\u015ft\u0131rmam\u0131za istekli olarak takviye veren hastalar\u0131m\u0131za ve eme\u011fi ge\u00e7en t\u00fcm s\u0131hhat profesyonellerine en i\u00e7ten \u015f\u00fckranlar\u0131m\u0131z\u0131 sunmak isteriz.\u201d<\/p>\n

Kaynak: (BYZHA) Beyaz Haber Ajans\u0131<\/p>\n","protected":false},"excerpt":{"rendered":"

T\u00fcrk ila\u00e7 dal\u0131n\u0131n en s\u00fcratli b\u00fcy\u00fcyen firmalar\u0131ndan biri olan GEN, sedef hastal\u0131\u011f\u0131n\u0131n tedavisine y\u00f6nelik geli\u015ftirdi\u011fi GN-037 tropikal kremi ile ilgili y\u00fcr\u00fct\u00fclen \u00e7al\u0131\u015fmalar\u0131ndan umut veren sonu\u00e7lar payla\u015ft\u0131.<\/p>\n","protected":false},"author":1,"featured_media":9284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[1561,2009,678,196,3313],"class_list":["post-9283","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik","tag-arastirma","tag-gen","tag-hasta","tag-tedavi","tag-topikal"],"_links":{"self":[{"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/posts\/9283"}],"collection":[{"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/comments?post=9283"}],"version-history":[{"count":1,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/posts\/9283\/revisions"}],"predecessor-version":[{"id":9285,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/posts\/9283\/revisions\/9285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/media\/9284"}],"wp:attachment":[{"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/media?parent=9283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/categories?post=9283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/yalovasondakika.com.tr\/index.php\/wp-json\/wp\/v2\/tags?post=9283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}